Synapse

← Steven A. Rosenberg

Papers by Steven A. Rosenberg

Page 5 · newest first

  1. Of Mice, Not Men: No Evidence for Graft-versus-Host Disease in Humans Receiving T-Cell Receptor–Transduced Autologous T CellsMolecular Therapy · 2010
  2. Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic AdenocarcinomaJournal of Immunotherapy · 2010
  3. Tumor Infiltrating Lymphocyte Therapy for Metastatic Melanoma: Analysis of Tumors Resected for TILJournal of Immunotherapy · 2010
  4. Successful Treatment of Melanoma Brain Metastases with Adoptive Cell TherapyClinical Cancer Research · 2010
  5. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19Blood · 2010
  6. CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic MelanomaClinical Cancer Research · 2010
  7. Rapid Production of Clinical-Grade Gammaretroviral Vectors in Expanded Surface Roller Bottles Using a “Modified” Step-Filtration Process for Clearance of Packaging CellsHuman Gene Therapy · 2010
  8. Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted HostsCancer Research · 2010
  9. Prevention of Interleukin-2 Withdrawal-Induced Apoptosis in Lymphocytes Retrovirally Cotransduced With Genes Encoding an Antitumor T-cell Receptor and an Antiapoptotic ProteinJournal of Immunotherapy · 2010
  10. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cellsBlood · 2010
  11. Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of CancerCancer Research · 2010
  12. Adoptive Cell TherapyThe Cancer Journal · 2010
  13. A Simplified Method for the Clinical-scale Generation of Central Memory-like CD8+ T Cells After Transduction With Lentiviral Vectors Encoding Antitumor Antigen T-cell ReceptorsJournal of Immunotherapy · 2010
  14. Enrichment of CD8+ Cells From Melanoma Tumor-infiltrating Lymphocyte Cultures Reveals Tumor Reactivity for Use in Adoptive Cell TherapyJournal of Immunotherapy · 2010
  15. Both CD4 and CD8 T Cells Mediate Equally Effective In Vivo Tumor Treatment When Engineered with a Highly Avid TCR Targeting TyrosinaseThe Journal of Immunology · 2010
  16. A High Molecular Weight Melanoma-Associated Antigen–Specific Chimeric Antigen Receptor Redirects Lymphocytes to Target Human MelanomasCancer Research · 2010
  17. Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2Molecular Therapy · 2010
  18. Increased Intensity Lymphodepletion Enhances Tumor Treatment Efficacy of Adoptively Transferred Tumor-specific T CellsJournal of Immunotherapy · 2009
  19. The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy aloneTrials · 2009
  20. A Herceptin-Based Chimeric Antigen Receptor with Modified Signaling Domains Leads to Enhanced Survival of Transduced T Lymphocytes and Antitumor ActivityThe Journal of Immunology · 2009
  21. Adoptively transferred effector cells derived from naïve rather than central memory CD8⁺T cells mediate superior antitumor immunityProceedings of the National Academy of Sciences · 2009
  22. Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen ReceptorJournal of Immunotherapy · 2009
  23. Lack of specific γ-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulationBlood · 2009
  24. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigenBlood · 2009
  25. Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impairedBlood · 2009
  26. Frequent mutations in the MITF pathway in melanomaPigment Cell & Melanoma Research · 2009
  27. Lentiviral Vector Design for Optimal T Cell Receptor Gene Expression in the Transduction of Peripheral Blood Lymphocytes and Tumor-Infiltrating LymphocytesHuman Gene Therapy · 2009
  28. Characterization of Genetically Modified T-Cell Receptors that Recognize the CEA:691-699 Peptide in the Context of HLA-A2.1 on Human Colorectal Cancer CellsClinical Cancer Research · 2008
  29. Mutational Inactivation of PTPRD in Glioblastoma Multiforme and Malignant MelanomaCancer Research · 2008
  30. Relationship of p53 Overexpression on Cancers and Recognition by Anti-p53 T Cell Receptor-Transduced T CellsHuman Gene Therapy · 2008
  31. Clinical-scale Lentiviral Vector Transduction of PBL for TCR Gene Therapy and Potential for Expression in Less-differentiated CellsJournal of Immunotherapy · 2008
  32. FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesionsBlood · 2008
  33. Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative RegimensJournal of Clinical Oncology · 2008
  34. Minimally Cultured Tumor-infiltrating Lymphocytes Display Optimal Characteristics for Adoptive Cell TherapyJournal of Immunotherapy · 2008
  35. Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriersBlood · 2008
  36. Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with VaccinesClinical Cancer Research · 2008
  37. Overcoming obstacles to the effective immunotherapy of human cancerProceedings of the National Academy of Sciences · 2008
  38. Influence of Cytotoxic T Lymphocyte-associated Antigen 4 (CTLA4) Common Polymorphisms on Outcome in Treatment of Melanoma Patients With CTLA-4 BlockadeJournal of Immunotherapy · 2008
  39. Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunityProceedings of the National Academy of Sciences · 2008
  40. High‐dose interleukin‐2 for the treatment of metastatic renal cell carcinomaCancer · 2008
  41. Single and Dual Amino Acid Substitutions in TCR CDRs Can Enhance Antigen-Specific T Cell FunctionsThe Journal of Immunology · 2008
  42. Adoptive Cell Therapy for Patients with Melanoma, Using Tumor-Infiltrating Lymphocytes Genetically Engineered to Secrete Interleukin-2Human Gene Therapy · 2008
  43. IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapyBlood · 2008
  44. Partial Reduction of Human FOXP3+ CD4 T Cells In Vivo After CD25-directed Recombinant Immunotoxin AdministrationJournal of Immunotherapy · 2008
  45. T-Cell Receptor Gene Therapy of Established Tumors in a Murine Melanoma ModelJournal of Immunotherapy · 2008
  46. Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 BlockadeClinical Cancer Research · 2007
  47. Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and HypophysitisJournal of Immunotherapy · 2007
  48. High-Affinity TCRs Generated by Phage Display Provide CD4+ T Cells with the Ability to Recognize and Kill Tumor Cell LinesThe Journal of Immunology · 2007
  49. Administration of a CD25-Directed Immunotoxin, LMB-2, to Patients with Metastatic Melanoma Induces a Selective Partial Reduction in Regulatory T Cells In VivoThe Journal of Immunology · 2007
  50. Toll-like Receptors in Tumor ImmunotherapyClinical Cancer Research · 2007